研发和临床评估多种研究用单价登革热疫苗，以确定用于四价减毒活疫苗的成分。
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.
机构信息
Center for Immunization Research, Department of International Health, Johns Hopkins Bloomberg School of Public Health, Baltimore, MD 21205, United States.
出版信息
Vaccine. 2011 Sep 23;29(42):7242-50. doi: 10.1016/j.vaccine.2011.07.023. Epub 2011 Jul 21.
Abstract
The Laboratory of Infectious Diseases at the National Institute of Allergy and Infectious Diseases, National Institutes of Health has been engaged in an effort to develop a safe, efficacious, and affordable live attenuated tetravalent dengue vaccine (LATV) for more than ten years. Numerous recombinant monovalent DENV vaccine candidates have been evaluated in the SCID-HuH-7 mouse and in rhesus macaques to identify those candidates with a suitable attenuation phenotype. In addition, the ability of these candidates to infect and disseminate in Aedes mosquitoes had also been determined. Those candidates that were suitably attenuated in SCID-HuH-7 mice, rhesus macaques, and mosquitoes were selected for further evaluation in humans. This review will describe the generation of multiple candidate vaccines directed against each DENV serotype, the preclinical and clinical evaluation of these candidates, and the process of selecting suitable candidates for inclusion in a LATV dengue vaccine.
摘要
美国国立卫生研究院过敏和传染病研究所传染病实验室十多年来一直致力于开发一种安全、有效且负担得起的四价减毒活登革热疫苗（LATV）。已经在 SCID-HuH-7 小鼠和恒河猴中评估了许多重组单价 DENV 疫苗候选物，以确定具有合适减毒表型的候选物。此外，还确定了这些候选物在埃及伊蚊中感染和传播的能力。在 SCID-HuH-7 小鼠、恒河猴和蚊子中适当减毒的候选物被选择用于进一步在人类中进行评估。这篇综述将描述针对每种 DENV 血清型的多种候选疫苗的产生、这些候选物的临床前和临床评估，以及选择合适的候选物纳入 LATV 登革热疫苗的过程。
相似文献
1
Development and clinical evaluation of multiple investigational monovalent DENV vaccines to identify components for inclusion in a live attenuated tetravalent DENV vaccine.研发和临床评估多种研究用单价登革热疫苗，以确定用于四价减毒活疫苗的成分。
Vaccine. 2011 Sep 23;29(42):7242-50. doi: 10.1016/j.vaccine.2011.07.023. Epub 2011 Jul 21.
2
Dengue vaccine candidates in development.正在研发中的登革热候选疫苗。
Curr Top Microbiol Immunol. 2010;338:129-43. doi: 10.1007/978-3-642-02215-9_10.
3
Using recombinant DNA technology for the development of live-attenuated dengue vaccines.利用重组 DNA 技术开发减毒活的登革热疫苗。
Enzyme Microb Technol. 2012 Jul 15;51(2):67-72. doi: 10.1016/j.enzmictec.2012.05.005. Epub 2012 May 17.
4
Vaccine candidates for dengue virus type 1 (DEN1) generated by replacement of the structural genes of rDEN4 and rDEN4Delta30 with those of DEN1.通过用1型登革病毒（DEN1）的结构基因替换rDEN4和rDEN4Delta30的结构基因而产生的1型登革病毒候选疫苗。
Virol J. 2007 Feb 28;4:23. doi: 10.1186/1743-422X-4-23.
5
Live attenuated tetravalent dengue virus host range vaccine is immunogenic in African green monkeys following a single vaccination.单价减毒登革热病毒宿主范围疫苗在单次接种后可在非洲绿猴体内产生免疫原性。
J Virol. 2014 Jun;88(12):6729-42. doi: 10.1128/JVI.00541-14. Epub 2014 Apr 2.
6
Generation and preclinical evaluation of a DENV-1/2 prM+E chimeric live attenuated vaccine candidate with enhanced prM cleavage.登革热病毒 1/2 型 prM+E 嵌合活疫苗候选株的构建及其增强前膜蛋白切割的初步评价
Vaccine. 2013 Oct 17;31(44):5134-40. doi: 10.1016/j.vaccine.2013.08.027. Epub 2013 Aug 22.
7
Development of TV003/TV005, a single dose, highly immunogenic live attenuated dengue vaccine; what makes this vaccine different from the Sanofi-Pasteur CYD™ vaccine?单剂量、高免疫原性减毒活登革热疫苗TV003/TV005的研发；该疫苗与赛诺菲-巴斯德CYD™疫苗有何不同？
Expert Rev Vaccines. 2016;15(4):509-17. doi: 10.1586/14760584.2016.1115727. Epub 2015 Dec 2.
8
Clinical evaluation strategies for a live attenuated tetravalent dengue vaccine.一种减毒活四价登革热疫苗的临床评估策略
Vaccine. 2015 Dec 10;33(50):7121-5. doi: 10.1016/j.vaccine.2015.09.105. Epub 2015 Oct 14.
9
Development of a recombinant, chimeric tetravalent dengue vaccine candidate.一种重组嵌合四价登革热候选疫苗的研发。
Vaccine. 2015 Dec 10;33(50):7112-20. doi: 10.1016/j.vaccine.2015.11.022. Epub 2015 Nov 14.
10
The dengue virus 4 component of NIAID's tetravalent TV003 vaccine drives its innate immune signature.NIAID 的四价 TV003 疫苗中的登革病毒 4 组分驱动其固有免疫特征。
Exp Biol Med (Maywood). 2022 Dec;247(24):2201-2212. doi: 10.1177/15353702231151241.
引用本文的文献
1
Vaccines Against Urban Epidemic Arboviruses: The State of the Art.针对城市流行性虫媒病毒的疫苗：现状
Viruses. 2025 Mar 6;17(3):382. doi: 10.3390/v17030382.
2
Development of a multi-epitope vaccine candidate to combat SARS-CoV-2 and dengue virus co-infection through an immunoinformatic approach.通过免疫信息学方法开发一种多表位候选疫苗，以对抗新冠病毒和登革病毒的共同感染。
Front Immunol. 2025 Feb 26;16:1442101. doi: 10.3389/fimmu.2025.1442101. eCollection 2025.
3
Localized Inflammation in Dengue Vaccine-Induced Skin Rash Is Not Associated with Continuous Presence of Dengue Virus Genome.登革热疫苗诱导的皮疹中的局部炎症与登革热病毒基因组的持续存在无关。
J Invest Dermatol. 2024 Dec 27. doi: 10.1016/j.jid.2024.11.015.
4
Precision arbovirus serology with a pan-arbovirus peptidome.泛虫媒病毒肽组学进行精准虫媒病毒血清学检测。
Nat Commun. 2024 Jul 11;15(1):5833. doi: 10.1038/s41467-024-49461-0.
5
Subgenomic flavivirus RNA as key target for live-attenuated vaccine development.亚基因组黄病毒 RNA 作为减毒活疫苗开发的关键靶标。
J Virol. 2024 Jul 23;98(7):e0010023. doi: 10.1128/jvi.00100-23. Epub 2024 May 29.
6
Approaches of dengue control: vaccine strategies and future aspects.登革热控制方法：疫苗策略和未来展望。
Front Immunol. 2024 Feb 29;15:1362780. doi: 10.3389/fimmu.2024.1362780. eCollection 2024.
7
Dengue.登革热。
Lancet. 2024 Feb 17;403(10427):667-682. doi: 10.1016/S0140-6736(23)02576-X. Epub 2024 Jan 24.
8
Host immunity and vaccine development against Dengue virus.针对登革病毒的宿主免疫与疫苗研发
Infect Med (Beijing). 2022 Feb 6;1(1):50-58. doi: 10.1016/j.imj.2021.12.003. eCollection 2022 Mar.
9
Flaviviruses in AntiTumor Therapy.黄病毒在抗肿瘤治疗中的作用。
Viruses. 2023 Sep 22;15(10):1973. doi: 10.3390/v15101973.
10
A stochastic B cell affinity maturation model to characterize mechanisms of protection for tetravalent dengue vaccine constructs.一种用于表征四价登革热疫苗构建体保护机制的随机B细胞亲和力成熟模型。
Front Mol Biosci. 2023 Jul 14;10:1100434. doi: 10.3389/fmolb.2023.1100434. eCollection 2023.
本文引用的文献
1
A novel tetravalent dengue vaccine is well tolerated and immunogenic against all 4 serotypes in flavivirus-naive adults.一种新型四价登革热疫苗在黄病毒初免成人中具有良好的耐受性和针对所有 4 种血清型的免疫原性。
J Infect Dis. 2010 Feb 1;201(3):370-7. doi: 10.1086/649916.
2
Phase 1 trial of the dengue virus type 4 vaccine candidate rDEN4{Delta}30-4995 in healthy adult volunteers.登革热病毒4型候选疫苗rDEN4{Delta}30 - 4995在健康成年志愿者中的1期试验。
Am J Trop Med Hyg. 2009 Nov;81(5):834-41. doi: 10.4269/ajtmh.2009.09-0131.
3
Targeted mutagenesis as a rational approach to dengue virus vaccine development.靶向突变作为登革热病毒疫苗开发的合理方法。
Curr Top Microbiol Immunol. 2010;338:145-58. doi: 10.1007/978-3-642-02215-9_11.
4
Evaluation of interferences between dengue vaccine serotypes in a monkey model.在猴模型中评估登革热疫苗血清型之间的干扰作用。
Am J Trop Med Hyg. 2009 Feb;80(2):302-11.
5
6
Phase 2 clinical trial of three formulations of tetravalent live-attenuated dengue vaccine in flavivirus-naïve adults.三价减毒活登革热疫苗在未感染黄病毒的成年人中的2期临床试验。 （注：原文是tetravalent，译文按正确内容翻译为“四价”，但你提供的英文原文可能有误，正常应为四价，而非三价）
Hum Vaccin. 2009 Jan-Feb;5(1):33-40. doi: 10.4161/hv.5.1.6348. Epub 2009 Jan 27.
7
Safety and immunogenicity of a tetravalent live-attenuated dengue vaccine in flavivirus naive children.四价减毒活登革热疫苗在未感染黄病毒儿童中的安全性和免疫原性。
Am J Trop Med Hyg. 2008 Mar;78(3):426-33.
8
Dengue virus type 3 vaccine candidates generated by introduction of deletions in the 3' untranslated region (3'-UTR) or by exchange of the DENV-3 3'-UTR with that of DENV-4.通过在3'非翻译区（3'-UTR）引入缺失或用登革病毒4型（DENV-4）的3'-UTR替换登革病毒3型（DENV-3）的3'-UTR而产生的登革病毒3型候选疫苗。
Vaccine. 2008 Feb 6;26(6):817-28. doi: 10.1016/j.vaccine.2007.11.082. Epub 2007 Dec 26.
9
10
Prevalence of neutropenia in the U.S. population: age, sex, smoking status, and ethnic differences.美国人群中性粒细胞减少症的患病率：年龄、性别、吸烟状况及种族差异。
Ann Intern Med. 2007 Apr 3;146(7):486-92. doi: 10.7326/0003-4819-146-7-200704030-00004.
Zotero 插件